Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMercia Asset Regulatory News (MERC)

Share Price Information for Mercia Asset (MERC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.50
Bid: 31.00
Ask: 32.00
Change: -0.20 (-0.63%)
Spread: 1.00 (3.226%)
Open: 31.50
High: 32.00
Low: 31.60
Prev. Close: 31.80
MERC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MIP Discovery positive progress update

8 Feb 2023 07:00

RNS Number : 2111P
Mercia Asset Management PLC
08 February 2023
 

RNS Reach

8 February 2023

 

Mercia Asset Management PLC

 

("Mercia", the "Group" or the "Company")

 

MIP Discovery positive progress update

 

Mercia Asset Management PLC (AIM: MERC), the proactive, regionally focused specialist asset manager with c.£1.4billion of assets under management, is pleased to share positive developments at MIP Discovery Limited ("MIP"), one of its direct investments.

 

MIP has recently announced that it has secured significant grant funding from the Bill & Melinda Gates Foundation. The funding will support a project focused on the use of MIP's detection reagents, to enable low-cost, high-volume diagnostic tests for low and middle-income countries, during endemic or pandemic outbreaks.

 

In parallel, MIP has announced the appointment of Brian Burke to its board as Chief Commercial Officer, bringing extensive experience from his tenure as Global Head of Strategy and Corporate Development at Horizon Discovery.

 

A Leicester University spinout, MIP was originally supported via Mercia's third-party managed funds. It is a nanotechnology business that has developed and patented a novel design and development process to make nano-scale molecularly imprinted polymers ("nanoMIPs"), that act as stable and highly cost-effective synthetic antibodies which require no animal testing and have a multitude of industrial applications. In addition to holding 20.1% via its managed funds, Mercia holds a fully diluted direct investment stake in MIP of 10.2%.

 

Dr Mark Payton, CEO of Mercia Asset Management PLC and non-executive Director on the MIP board commented: "We are excited by the continued progress being seen at MIP. Attracting funding from the Bill & Melinda Gates Foundation is testament to the significant potential of MIP's platform technology to solve critical diagnostic challenges and deliver solutions that meaningfully improve healthcare outcomes, in the parts of the world that most need help. Brian's appointment also strengthens its executive team and will bring valuable commercial expertise, as MIP takes specific products in development toward material market opportunities."

 

 

 -Ends-

 

For further information, please contact:

 

Mercia Asset Management PLC

Mark Payton, Chief Executive Officer

Martin Glanfield, Chief Financial Officer

www.mercia.co.uk

 

+44 (0)330 223 1430

 

Canaccord Genuity Limited (NOMAD and Joint Broker)

+44 (0)20 7523 8000

Simon Bridges, Emma Gabriel

Singer Capital Markets (Joint Broker)

+44 (0)20 7496 3000

Harry Gooden, James Moat

FTI Consulting

+44 (0)20 3727 1051

Tom Blackwell, Immy Ransom

mercia@fticonsulting.com

 

About Mercia Asset Management PLC

 

Mercia is a proactive, specialist asset manager focused on supporting regional SMEs to achieve their growth aspirations. Mercia provides capital across its four asset classes of venture, private equity, debt and proprietary capital: the Group's 'Complete Connected Capital'. The Group initially nurtures businesses via its third-party funds under management, then over time Mercia can provide further funding to the most promising companies, by deploying direct investment follow-on capital from its own balance sheet.

 

The Group has a strong UK footprint through its regional offices, university partnerships and extensive personal networks, providing it with access to high-quality deal flow.

 

Mercia Asset Management PLC is quoted on AIM with the EPIC "MERC".

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUPURPPUPWGAM
Date   Source Headline
21st Sep 20187:00 amRNSAGM Statement
18th Sep 20187:00 amRNSAston EyeTech secures multi-million pound contract
13th Sep 20187:00 amRNSNotice of Capital Markets Day
29th Aug 20187:00 amRNSGrant of Options
16th Aug 20187:00 amRNSnDreams secures multi-million dollar contract
7th Aug 20187:00 amRNSOG wins significant multi-million pound contract
27th Jul 20189:30 amRNSPublication of Annual Report
17th Jul 20183:14 pmRNSPDMR / Director Dealings
2nd Jul 20187:00 amRNSPreliminary Results
20th Jun 20187:00 amRNSVirtTrade secures partnership with Formula 1
12th Jun 20187:00 amRNSBoard Appointment
21st May 20187:00 amRNSNotice of Preliminary Results
17th Apr 20187:00 amRNSBoard Change
26th Mar 20187:00 amRNSDeferred Consideration and Board Change
22nd Mar 20187:00 amRNSNew Direct Investment in Voxpopme
2nd Mar 20187:00 amRNSSale of Science Warehouse Limited
1st Feb 20187:00 amRNSMercia Annual Gala Dinner
22nd Dec 20177:00 amRNSBoard Appointment
18th Dec 20177:00 amRNSAmendment to Share Options
13th Dec 20177:00 amRNS£5.0million syndicated investment into Intechnica
11th Dec 20177:00 amRNS£3.8million syndicated investment into Medherant
6th Dec 20177:00 amRNSHalf Year Results
24th Nov 20177:00 amRNSImpression Technologies secures grant funding
17th Nov 20177:00 amRNSNew Direct Investment in £5.0m syndicated round
14th Nov 20177:00 amRNSLife Sciences & Biosciences sector update
1st Nov 20177:00 amRNSNew Partnership with the University of Edinburgh
31st Oct 20177:00 amRNSNotice of Results
25th Oct 20177:00 amRNSAppointment of Joint Broker
5th Oct 20177:00 amRNSFurther significant fund realisation achieved
3rd Oct 20177:00 amRNSWebsite launch
20th Sep 20177:00 amRNS£3.1million syndicated investment
18th Sep 201711:05 amRNSResult of AGM
18th Sep 20177:00 amRNSAGM statement
21st Aug 20177:00 amRNS£2.0m investment into Oxford Genetics
2nd Aug 20177:00 amRNSBoard Change
25th Jul 20177:00 amRNSGrant Options & PDMR Dealings
21st Jul 20177:00 amRNSPublication of Annual Report
13th Jul 20177:00 amRNSMercia invests additional £2.0million into nDreams
3rd Jul 20177:00 amRNSPreliminary results
21st Jun 20177:00 amRNSInvestment into Impression Tech & Sector Update
6th Jun 20177:00 amRNSFurther investment into Oxford Genetics
3rd May 20177:00 amRNSNotice of Preliminary Results
22nd Feb 20177:00 amRNSTwo major contracts for Northern Powerhouse Funds
17th Feb 201712:00 pmRNSNotification of Major Interest in Shares
16th Feb 201710:43 amRNSResult of General Meeting & Completion of Placing
31st Jan 20172:40 pmRNSPlacing of new Ordinary Shares to raise c.£40.0m
26th Jan 20177:00 amRNSNotice of Mercia Annual Gala Dinner
18th Jan 20177:00 amRNSNew Direct Investment in Faradion Limited
16th Dec 20167:00 amRNSSale of Allinea Software Limited to ARM
16th Nov 20167:00 amRNS£1m invested in nDreams as part of £2m syndication

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.